152 related articles for article (PubMed ID: 38224706)
1. Safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnant women with HIV from Gabon and Mozambique: a randomised, double-blind, placebo-controlled trial.
González R; Nhampossa T; Mombo-Ngoma G; Mischlinger J; Esen M; Tchouatieu AM; Mendes A; Figueroa-Romero A; Zoleko-Manego R; Lell B; Lagler H; Stoeger L; Dimessa LB; El Gaaloul M; Sanz S; Méndez S; Piqueras M; Sevene E; Ramharter M; Saúte F; Menendez C;
Lancet Infect Dis; 2024 May; 24(5):476-487. PubMed ID: 38224706
[TBL] [Abstract][Full Text] [Related]
2. Chemoprevention for malaria with monthly intermittent preventive treatment with dihydroartemisinin-piperaquine in pregnant women living with HIV on daily co-trimoxazole in Kenya and Malawi: a randomised, double-blind, placebo-controlled trial.
Barsosio HC; Madanitsa M; Ondieki ED; Dodd J; Onyango ED; Otieno K; Wang D; Hill J; Mwapasa V; Phiri KS; Maleta K; Taegtmeyer M; Kariuki S; Schmiegelow C; Gutman JR; Ter Kuile FO
Lancet; 2024 Jan; 403(10424):365-378. PubMed ID: 38224710
[TBL] [Abstract][Full Text] [Related]
3. Effect of monthly intermittent preventive treatment with dihydroartemisinin-piperaquine with and without azithromycin versus monthly sulfadoxine-pyrimethamine on adverse pregnancy outcomes in Africa: a double-blind randomised, partly placebo-controlled trial.
Madanitsa M; Barsosio HC; Minja DTR; Mtove G; Kavishe RA; Dodd J; Saidi Q; Onyango ED; Otieno K; Wang D; Ashorn U; Hill J; Mukerebe C; Gesase S; Msemo OA; Mwapasa V; Phiri KS; Maleta K; Klein N; Magnussen P; Lusingu JPA; Kariuki S; Mosha JF; Alifrangis M; Hansson H; Schmiegelow C; Gutman JR; Chico RM; Ter Kuile FO
Lancet; 2023 Mar; 401(10381):1020-1036. PubMed ID: 36913959
[TBL] [Abstract][Full Text] [Related]
4. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial.
Desai M; Gutman J; L'lanziva A; Otieno K; Juma E; Kariuki S; Ouma P; Were V; Laserson K; Katana A; Williamson J; ter Kuile FO
Lancet; 2015 Dec; 386(10012):2507-19. PubMed ID: 26429700
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. Mefloquine for preventing malaria in pregnant women.
González R; Pons-Duran C; Piqueras M; Aponte JJ; Ter Kuile FO; Menéndez C
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD011444. PubMed ID: 29561063
[TBL] [Abstract][Full Text] [Related]
7. Mefloquine for preventing malaria in pregnant women.
González R; Pons-Duran C; Piqueras M; Aponte JJ; Ter Kuile FO; Menéndez C
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD011444. PubMed ID: 30480761
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women: protocol of a multicentre, two-arm, randomised, placebo-controlled, superiority clinical trial (MAMAH project).
González R; Nhampossa T; Mombo-Ngoma G; Mischlinger J; Esen M; Tchouatieu AM; Pons-Duran C; Dimessa LB; Lell B; Lagler H; Garcia-Otero L; Zoleko Manego R; El Gaaloul M; Sanz S; Piqueras M; Sevene E; Ramharter M; Saute F; Menendez C
BMJ Open; 2021 Nov; 11(11):e053197. PubMed ID: 34815285
[TBL] [Abstract][Full Text] [Related]
9. Intermittent preventive treatment with dihydroartemisinin-piperaquine and risk of malaria following cessation in young Ugandan children: a double-blind, randomised, controlled trial.
Muhindo MK; Jagannathan P; Kakuru A; Opira B; Olwoch P; Okiring J; Nalugo N; Clark TD; Ruel T; Charlebois E; Feeney ME; Havlir DV; Dorsey G; Kamya MR
Lancet Infect Dis; 2019 Sep; 19(9):962-972. PubMed ID: 31307883
[TBL] [Abstract][Full Text] [Related]
10. Monthly sulfadoxine-pyrimethamine versus dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in pregnancy: a double-blind, randomised, controlled, superiority trial.
Kajubi R; Ochieng T; Kakuru A; Jagannathan P; Nakalembe M; Ruel T; Opira B; Ochokoru H; Ategeka J; Nayebare P; Clark TD; Havlir DV; Kamya MR; Dorsey G
Lancet; 2019 Apr; 393(10179):1428-1439. PubMed ID: 30910321
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of intermittent preventive treatment and intermittent screening and treatment versus single screening and treatment with dihydroartemisinin-piperaquine for the control of malaria in pregnancy in Indonesia: a cluster-randomised, open-label, superiority trial.
Ahmed R; Poespoprodjo JR; Syafruddin D; Khairallah C; Pace C; Lukito T; Maratina SS; Asih PBS; Santana-Morales MA; Adams ER; Unwin VT; Williams CT; Chen T; Smedley J; Wang D; Faragher B; Price RN; Ter Kuile FO
Lancet Infect Dis; 2019 Sep; 19(9):973-987. PubMed ID: 31353217
[TBL] [Abstract][Full Text] [Related]
12. Scheduled Intermittent Screening with Rapid Diagnostic Tests and Treatment with Dihydroartemisinin-Piperaquine versus Intermittent Preventive Therapy with Sulfadoxine-Pyrimethamine for Malaria in Pregnancy in Malawi: An Open-Label Randomized Controlled Trial.
Madanitsa M; Kalilani L; Mwapasa V; van Eijk AM; Khairallah C; Ali D; Pace C; Smedley J; Thwai KL; Levitt B; Wang D; Kang'ombe A; Faragher B; Taylor SM; Meshnick S; Ter Kuile FO
PLoS Med; 2016 Sep; 13(9):e1002124. PubMed ID: 27622558
[TBL] [Abstract][Full Text] [Related]
13. Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial.
Jagannathan P; Kakuru A; Okiring J; Muhindo MK; Natureeba P; Nakalembe M; Opira B; Olwoch P; Nankya F; Ssewanyana I; Tetteh K; Drakeley C; Beeson J; Reiling L; Clark TD; Rodriguez-Barraquer I; Greenhouse B; Wallender E; Aweeka F; Prahl M; Charlebois ED; Feeney ME; Havlir DV; Kamya MR; Dorsey G
PLoS Med; 2018 Jul; 15(7):e1002606. PubMed ID: 30016328
[TBL] [Abstract][Full Text] [Related]
14. Intermittent preventive treatment of malaria in pregnancy with mefloquine in HIV-infected women receiving cotrimoxazole prophylaxis: a multicenter randomized placebo-controlled trial.
González R; Desai M; Macete E; Ouma P; Kakolwa MA; Abdulla S; Aponte JJ; Bulo H; Kabanywanyi AM; Katana A; Maculuve S; Mayor A; Nhacolo A; Otieno K; Pahlavan G; Rupérez M; Sevene E; Slutsker L; Vala A; Williamsom J; Menéndez C
PLoS Med; 2014 Sep; 11(9):e1001735. PubMed ID: 25247995
[TBL] [Abstract][Full Text] [Related]
15. Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Kakuru A; Jagannathan P; Muhindo MK; Natureeba P; Awori P; Nakalembe M; Opira B; Olwoch P; Ategeka J; Nayebare P; Clark TD; Feeney ME; Charlebois ED; Rizzuto G; Muehlenbachs A; Havlir DV; Kamya MR; Dorsey G
N Engl J Med; 2016 Mar; 374(10):928-39. PubMed ID: 26962728
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of intermittent presumptive treatment with sulfadoxine-pyrimethamine using rapid diagnostic test screening and treatment with dihydroartemisinin-piperaquine at the first antenatal care visit (IPTp-SP+): study protocol for a randomized controlled trial.
Kabuya JB; Ippolito MM; Sikalima J; Tende C; Champo D; Mwakazanga D; Young AMP; Mulenga M; Chongwe G; Manyando C
Trials; 2021 Nov; 22(1):820. PubMed ID: 34801059
[TBL] [Abstract][Full Text] [Related]
17. Single low-dose tafenoquine combined with dihydroartemisinin-piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trial.
Stone W; Mahamar A; Smit MJ; Sanogo K; Sinaba Y; Niambele SM; Sacko A; Keita S; Dicko OM; Diallo M; Maguiraga SO; Samake S; Attaher O; Lanke K; Ter Heine R; Bradley J; McCall MBB; Issiaka D; Traore SF; Bousema T; Drakeley C; Dicko A
Lancet Microbe; 2022 May; 3(5):e336-e347. PubMed ID: 35544095
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of intermittent preventive treatment with dihydroartemisinin-piperaquine for malaria during pregnancy: an analysis using efficacy results from Uganda and Kenya, and pooled data.
Fernandes S; Were V; Gutman J; Dorsey G; Kakuru A; Desai M; Kariuki S; Kamya MR; Ter Kuile FO; Hanson K
Lancet Glob Health; 2020 Dec; 8(12):e1512-e1523. PubMed ID: 33137287
[TBL] [Abstract][Full Text] [Related]
19. Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.
West African Network for Clinical Trials of Antimalarial Drugs (WANECAM)
Lancet; 2018 Apr; 391(10128):1378-1390. PubMed ID: 29606364
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of intermittent preventive treatment with dihydroartemisinin-piperaquine or artesunate-amodiaquine for reducing malaria and related morbidities in schoolchildren in Tanzania: a randomised controlled trial.
Makenga G; Baraka V; Francis F; Nakato S; Gesase S; Mtove G; Madebe R; Kyaruzi E; Minja DTR; Lusingu JPA; Geertruyden JV
Lancet Glob Health; 2023 Aug; 11(8):e1277-e1289. PubMed ID: 37474234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
